Arecor Therapeutics plc
AREC.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.00 | -0.13 | 0.26 |
| FCF Yield | -7.56% | -17.85% | -11.37% | -2.68% |
| EV / EBITDA | -6.08 | -4.42 | -7.58 | -12.56 |
| Quality | ||||
| ROIC | -99.47% | -47.16% | -129.03% | -33.89% |
| Gross Margin | 16.38% | -21.98% | 111.03% | 110.37% |
| Cash Conversion Ratio | 0.46 | 0.88 | 0.90 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 47.50% | 38.94% | 39.01% | 38.27% |
| Free Cash Flow Growth | 74.95% | -18.57% | -178.72% | 65.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.70 | 0.54 | 0.49 | 1.17 |
| Interest Coverage | -382.88 | -280.30 | -657.83 | -361.10 |
| Efficiency | ||||
| Inventory Turnover | 14.96 | 7.34 | -0.49 | 0.25 |
| Cash Conversion Cycle | 14.12 | 75.35 | 828.91 | -591.95 |